Treatment with letrozole, to which the tumors acquired resistance, failed to inhibit growth with the mean tumor volume reaching > 200% from baseline treatment at 10 weeks, whereas treatment with fulvestrant, a known potent selective estrogen receptor degrader (SERD), markedly inhibited tumor growth (Fig. 1c). This evidence concerns the gene ESR1 and neoplasm.